Jean-Louis Houpeau1, Marie-Pierre Chauvet1, François Guillemin2, Cécile Bendavid-Athias3, Hélène Charitansky4, Andrew Kramar5, Sylvia Giard1. 1. Department of Senology, Centre Oscar Lambret, Lille Cedex, France. 2. Department of Surgical Oncology, Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandoeuvre les Nancy, France. 3. Department of Surgical Oncology, Centre Eugène Marquis, Rennes Cedex, France. 4. Department of Surgical Oncology, Institut Claudius Regaud, Toulouse Cedex, France. 5. Department of Biostatistic, Centre Oscar Lambret, Lille Cedex, France.
Abstract
BACKGROUND AND OBJECTIVES: The French Sentimag feasibility trial evaluated a new method for the localization of breast cancer sentinel lymph node (SLN) using Sienna+®, superparamagnetic iron oxide particles, and Sentimag® detection in comparison to the standard technique (isotopes ± blue dye). METHODS: We conducted a prospective multicentric paired comparison trial on 115 patients. SLN localization was performed using both the magnetic technique and the standard method. Detection rate and concordance between magnetic and standard tracers were calculated. Post-operative complications were assessed after 30 days. RESULTS: Results are based on 108 patients. SLN identification rate was 98.1% [93.5-99.8] for both methods, 97.2% [92.1-99.4] for Sienna+® and 95.4% [89.5-98.5] for standard technique. A mean of 2.1 SLNs per patient was removed. The concordance rate was 99.0% [94.7-100.0%] per patient and 97.4% [94.1-99.2] per node. Forty-six patients (43.4%) had nodal involvement. Among involved SLNs, concordance rate was 97.7% [88.0-99.9] per patient and 98.1% [90.1-100.0] per node. CONCLUSIONS: This new magnetic tracer is a feasible method and a promising alternative to the isotope. It could offer benefits for ambulatory surgery or sites without nuclear medicine departments. J. Surg. Oncol. 2016;113:501-507.
BACKGROUND AND OBJECTIVES: The French Sentimag feasibility trial evaluated a new method for the localization of breast cancer sentinel lymph node (SLN) using Sienna+®, superparamagnetic iron oxide particles, and Sentimag® detection in comparison to the standard technique (isotopes ± blue dye). METHODS: We conducted a prospective multicentric paired comparison trial on 115 patients. SLN localization was performed using both the magnetic technique and the standard method. Detection rate and concordance between magnetic and standard tracers were calculated. Post-operative complications were assessed after 30 days. RESULTS: Results are based on 108 patients. SLN identification rate was 98.1% [93.5-99.8] for both methods, 97.2% [92.1-99.4] for Sienna+® and 95.4% [89.5-98.5] for standard technique. A mean of 2.1 SLNs per patient was removed. The concordance rate was 99.0% [94.7-100.0%] per patient and 97.4% [94.1-99.2] per node. Forty-six patients (43.4%) had nodal involvement. Among involved SLNs, concordance rate was 97.7% [88.0-99.9] per patient and 98.1% [90.1-100.0] per node. CONCLUSIONS: This new magnetic tracer is a feasible method and a promising alternative to the isotope. It could offer benefits for ambulatory surgery or sites without nuclear medicine departments. J. Surg. Oncol. 2016;113:501-507.
Authors: Sina Shams; Kai Lippold; Jens Uwe Blohmer; Robert Röhle; Friedrich Kühn; Maria Margarete Karsten Journal: Ann Surg Oncol Date: 2020-12-01 Impact factor: 5.344
Authors: Andreas Karakatsanis; Peer Michael Christiansen; Lone Fischer; Christina Hedin; Lida Pistioli; Malin Sund; Nils Ryegaard Rasmussen; Hjørdis Jørnsgård; Daniel Tegnelius; Staffan Eriksson; Kosmas Daskalakis; Fredrik Wärnberg; Christos J Markopoulos; Leif Bergkvist Journal: Breast Cancer Res Treat Date: 2016-04-27 Impact factor: 4.872